Production (Stage)
Skye Bioscience, Inc.
SKYE
$1.99
-$0.21-9.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 58.80% | 3,260.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -100.00% | |||
| Total Operating Expenses | 10.25% | 114.63% | |||
| Operating Income | -10.25% | -114.63% | |||
| Income Before Tax | -13.90% | -150.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.92% | -150.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.92% | -150.02% | |||
| EBIT | -10.25% | -114.63% | |||
| EBITDA | -10.40% | -113.94% | |||
| EPS Basic | -14.80% | -142.93% | |||
| Normalized Basic EPS | -15.97% | -115.26% | |||
| EPS Diluted | -14.80% | -142.93% | |||
| Normalized Diluted EPS | -15.97% | -115.26% | |||
| Average Basic Shares Outstanding | -0.79% | 2.96% | |||
| Average Diluted Shares Outstanding | -0.79% | 2.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||